Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417–33.
Moras M, Lefevre SD, Ostuni MA. From erythroblasts to mature red blood cells: organelle clearance in mammals. Front Physiol. 2017;8:1076.
Nguyen AT, Prado MA, Schmidt PJ, Sendamarai AK, Wilson-Grady JT, Min M, et al. UBE2O remodels the proteome during terminal erythroid differentiation. Science. 2017;357:eaan0218.
Moura PL, Hawley BR, Mankelow TJ, Griffiths RE, Dobbe JGG, Streekstra GJ, et al. Non-muscle myosin II drives vesicle loss during human reticulocyte maturation. Haematologica. 2018;103:1997–2007.
Giarratana M-C, Kobari L, Lapillonne H, Chalmers D, Kiger L, Cynober T, et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat Biotechnol. 2004;23:69–74.
Rankin EB, Wu C, Khatri R, Andersen R, Araldi E, Rankin AL, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149:63–74.
Shah S, Huang X, Cheng L. Concise review: stem cell-based approaches to red blood cell production for transfusion. Stem Cells Transl Med. 2013;3:346–55.
O’Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085–91.
Perron G, Jandaghi P, Solanki S, Safisamghabadi M, Storoz C, Karimzadeh M, et al. A general framework for interrogation of mRNA stability programs identifies RNA-binding proteins that govern cancer transcriptomes. Cell Rep. 2018;23:1639–50.
Bresson S, Tollervey D. Tailing off: PABP and CNOT generate cycles of mRNA deadenylation. Mol Cell. 2018;70:987–8.
Delforge M, Dhawan R, Robinson D, Meunier J, Regnault A, Esseltine D-L, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89:16–27.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777–84.
Carulli G, Marini A, Azzarà A, Lucchetti A, Petrini M. Pseudoreticulocytosis in a case of myelodysplastic syndrome. Acta Haematol. 1998;100:156–8.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2014;372:142–52.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27.
This study was supported in part by the UZ Leuven Janssen Hematology Fund and “the Luc Fraiture” Fund. We would like to acknowledge Dr Christa Maes for providing the osteoblastic cell lines and Mrs Annouschka Laenen (L-Biostat and Leuven Cancer Institute, KU Leuven, Belgium) for statistical support, Dr Francis Impens (Proteomics Expertise Center, Flemish Institute of Biotechnology, Ghent, Belgium) for processing and analyzing the LC-MS/MS data and Somersault 18:24 (Diest, Belgium) for their assistance in constructing Fig. 2c.
Conflict of interest
NK: travel support from Celgene, Amgen and Takeda, MD: speaker’s honoraria from Amgen, Celgene, Janssen, Takeda. Other authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kint, N.G., Heylen, E., Pepe, D. et al. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation. Leukemia 34, 651–655 (2020). https://doi.org/10.1038/s41375-019-0565-y